64 results about "Cell delivery" patented technology

The present invention relates to a stretchable self-healing hydrogel. The hydrogel has excellent mechanical properties and stability, and stretchable and self-healing properties, and can be useful as a hydrogel for delivery of a drug or a cell, and a composition for 3D bioprinters.

Provided herein are methods of preparing an engineered heart valve for implantation into a subject in need (e.g., a pediatric patient). For example, a porcine pulmonary valve can be decellularized and then recellularized with cells from the subject. Hydrogels can be used to facilitate cell delivery and growth within the sub-endothelial layer (e.g., spongiosa) of a heart valve, which is essential for long-term success of the implantation.

The present disclosure is directed to various compositions that include one or more energy source components; one or more pH buffers; one or more salts; and one or more stabilizing agents and one or more cell types.

[Problem to be Solved]Provided is a delivery carrier into the cell having high antioxidant activity, intracellular absorbability, intracellular disintegration property, stability and safety, which have high delivery property of the active ingredient to cell and living tissues.[Solution]The delivery carrier into cells includes a vitamin derivative with co-activation of both autophagy-related genes and protease synthesis genes, a polymer molecule containing stimulatory reactivity, an emulsion stabilizer, an active ingredient, and a lipid, thereby providing a delivery carrier into cells with high delivery properties of the active ingredient to cells and living tissues.

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

A method of preparing a syringe in connection with a therapeutic treatment is disclosed. The method can include removing a plunger of the syringe from a barrel of the syringe, aligning the barrel in a horizontal orientation, filling a lumen of the barrel with a viscous material through an opening at a proximal end of the barrel, and inserting a plunger tip into the lumen to seal the lumen. The method can also include attaching an implantation device to a hub coupled to the barrel at a distal end of the barrel. The method can also include depressing the plunger until the cell suspension fills the implantation device and a droplet of the cell suspension is expelled from a distal tip of the implantation device.

The present invention relates to the field of the synthesis of polymers. Disclosed are a polypropyleneimine derivative, and a preparation method therefor and a use thereof. The method comprises: firstly, initiating polymerization of an oxazine derivative monomer by means of an initiator, then removing a side chain from a polymer to obtain polypropyleneimine, selecting the polypropyleneimine for a further reaction to obtain a zwitterionic precursor polymer, and finally, hydrolyzing the precursor polymer to obtain a polypropyleneimine zwitterionic derivative. The polypropyleneimine zwitterionic derivative prepared in the present application contains a zwitterionic group in each or some of repeating units. The zwitterionic group endows the polymer with good hydrophilicity and anti-protein non-specific adsorption properties. The polymer has no immunogenicity, will not be recognized by the immune system and captured by immune cells, can be used as a drug carrier and a gene vehicle, and has good blood circulation stability. Alternatively, the polymer is used as a biological material, a medical device, an implantable material, or a cell delivery material and has good anticoagulation, anti-rejection, and biofilm properties.

The invention relates to the technical field of medical engineering, in particular to an NK cell delivery data processing method and system based on magnetic targeting. The method comprises the following steps: inquiring an immune receptor protein structure of natural killer cells; injecting a sodium chloride solution, adding an immune receptor protein structure, and reacting to generate an aptamer structure; the method comprises the following steps: combining streptavidin in a pre-prepared glycosyl magnetic microsphere to obtain a high-affinity magnetic bead; carrying out molecular docking on the high-affinity magnetic beads and the aptamer structure, recording a docking score, and generating an optimized aptamer; recording the magnetic bead mass ratio of the optimized aptamer; capturing the natural killer cells by adopting the optimized aptamer, and shooting to obtain a fluorescent microscopic image; and recording the dyeing condition of the fluorescent microscopic image, determining the survival state of the NK cells, marking the position information of the living cells, and generating an NK cell delivery efficiency table by using the mass ratio of the magnetic beads. Based on a medical engineering technology, the homing rate and the delivery efficiency of the NK cells at the liver injury part are improved.

The present disclosure relates to methods and compositions comprising a universal cell delivery ligand configured to enhance the intratumoral delivery and distribution of therapeutic immune cells by facilitating their penetration through dense stroma surrounding tumor cells.

This invention belongs to the field of biomedical technology, specifically relating to lipid nanoparticles, their preparation method, and their application in immune cell delivery. This invention introduces amino acid-derived lipids as a fifth component into a preferred four-component formulation. Furthermore, through screening of the nitrogen-to-phosphorus ratio, the proportion of amino acid-derived lipids introduced, and the type of amino acid-derived lipids, novel lipid nanoparticles capable of efficiently delivering primary immune cells are selected. The delivery carrier described in this invention can significantly improve the delivery efficiency to primary immune cells, especially NK cells, providing a safe and efficient tool for the engineering of immune cells and their clinical application in immune cell therapy.

The invention provides a Motixazotide-nitrogen mustard conjugate and a preparation method and application of a fluorescent probe of the Motixazotide-nitrogen mustard conjugate, and belongs to the field of polypeptide preparation and biological medicine. According to the present invention, a solid phase polypeptide synthesis method is adopted to covalently link a DNA alkylation reagent nitrogen mustard and a CXCR4 targeting peptide Motixazotide, and further couple with a fluorescent dye so as to successfully prepare a series of novel conjugates and fluorescent probes thereof; experiments prove that the Motixazotide-nitrogen mustard conjugate and the fluorescent probe thereof prepared by the invention can be used for remarkably improving the anti-tumor activity of nitrogen mustard and the targeting property of the nitrogen mustard to tumor cells. Meanwhile, the rhodamine B labeled dinitrogen mustard conjugate BCCR has a specific targeting effect on a CXCR4 receptor and a dual targeting effect on a tumor cell nucleus. The conjugate realizes real-time tracing of the whole process of tumor targeting, cell delivery and nuclear localization, and provides a powerful tool for curative effect evaluation and mechanism research, so that the conjugate has good clinical transformation prospect and application value.

The invention relates to the field of gene therapy. In addition the invention relates to the field of interfering RNA and / or microRNA (miRNA). In particular the invention relates to gene therapy involving such miRNA's and more in particular to methods and means to improve delivery of said miRNAs to target cells of a patient. The invention provides for a gene delivery vehicle for use in delivery of a miRNA to a cell resulting in silencing of a desired gene and whereby spread of said miRNA to other non-transduced cells results in silencing of said desired gene in said non-transduced cells.

The invention belongs to the technical field of biological medicine, and particularly relates to lipid nanoparticles, a preparation method thereof and application of the lipid nanoparticles in immune cell delivery. According to the invention, amino acid derived lipid is introduced as a fifth component on the basis of a preferable four-component formula. Through screening of the nitrogen-phosphorus ratio, the introduction proportion of the amino acid-derived lipid and the type of the amino acid-derived lipid, the novel lipid nanoparticles capable of efficiently delivering the primary immune cells are preferably selected. According to the delivery carrier, the delivery efficiency of primary immune cells, especially NK cells, can be remarkably improved, and a safe and efficient tool is provided for clinical application of immune cell engineering and immune cell treatment.

The invention provides an enzyme-residue-free extracellular matrix microsphere as well as a preparation method and application thereof. An elutable sacrificial phase material capable of being subjected to liquid-liquid phase separation with an extracellular matrix is introduced in an extracellular matrix pelletizing process, and transglutaminase is confined in a sacrificial phase, so that the extracellular matrix microsphere is prepared. And the transglutaminase and the extracellular matrix form a spatially separated structure in the balling process. In the gel forming stage, transglutaminase catalyzes protein in an extracellular matrix on a two-phase interface to generate a cross-linking reaction, and microspheres with a three-dimensional network gel structure are formed; after cross-linking is completed, transglutaminase is removed by eluting the sacrificial phase material, and meanwhile, a porous network with a communicated structure is formed in situ in the microsphere, so that the obtained extracellular matrix microsphere still keeps good structural integrity and mechanical property while realizing no residue of enzyme with catalytic activity; the scaffold can provide stable support for cell adhesion, migration and three-dimensional culture, and is applicable to cell delivery, organoid construction, tissue engineering scaffolds and the like.

Provided herein are, inter alia, extracellular products (e.g., vesicles such as microvesicles, e.g., exosomes) produced by renal cells (such as bioactive renal cells, e.g., selected renal cells). Methods of altering components (such as miRNAs or proteins) of vesicles produced by cells, as well as methods of producing vesicles comprising various compounds are also included. Also provided are diagnostic and treatment methods.

An isolated, non-naturally occurring cell penetrating peptide (CPP) comprising the amino acid sequence: RRSRTARAGRPGRNSSRPSAPR [SEQ ID NO: 1] and sequences having at least 60% similarity to SEQ ID NO: 1.

The present disclosure presents hydrogel compositions for use in the treatment of an ocular disorder (e.g., a retinal disease) and methods of treating an ocular disorder in a subject in need thereof with the hydrogel compositions. The hydrogel compositions can include hydroxyphenylpropionic acid (gelatin-HPA), hyaluronic acid-tyramine (HA-Tyr), a catalyzer (e.g., horseradish peroxidase (HRP)), a cell, a crosslinker (e.g., hydrogen peroxide), or any combination thereof. The methods include administering a therapeutically effective amount of a composition into an eye of the subject, wherein the composition includes any of the hydrogel compositions of the disclosure.

A system for delivering a therapeutic composition to a patient, the system including: a container configured to hold the therapeutic composition; at least one powered driver operatively connected to the container; a plurality of sensors including at least two of: (i) a pressure sensor, (ii) a flow sensor, (iii) a counting sensor, (iv) a site sensor, (v) a temperature sensor, (vi) a chemical sensor, and (vii) at least one physiological sensor; and at least one processor programmed or configured to receive data from the plurality of sensors and control the at least one powered driver to infuse the therapeutic composition into the patient at a desired flow rate, the magnitude of which is dependent on the data received from the plurality of sensors.

The invention belongs to the technical field of biological medicines, and particularly relates to a stapled strategy modified polypeptide and application thereof. The invention designs and synthesizes a stripled-modified polypeptide containing a permeable membrane peptide and an alpha spiral fragment and a polypeptide carrier. The polypeptide and the polypeptide carrier provided by the invention have good delivery capacity, stability and biocompatibility, are relatively low in toxicity, and can effectively improve the problems of cell delivery of nucleic acid or drugs, endosome escape and the like. After stapled modification, the stability of the polypeptide carrier is greatly improved, and the polypeptide carrier has the potential of being developed as a delivery carrier.

The present invention relates to the field of biomedicine, and more specifically, to a drug delivery system for delivering drugs to cells. The drug delivery system disclosed herein comprises a drug delivery vehicle encapsulating a nucleic acid drug and photothermal nanoparticles. This drug delivery system pioneers an unprecedented approach to intracellular drug delivery, utilizing materials that are biocompatible, environmentally friendly, and pollution-free. Furthermore, compared to other methods, it is simpler and more convenient to operate, with lower production and application costs and a more economical and user-friendly approach.

Artificial antigen presenting cells (aAPC) including a major histocompatibility class II (MHC II) molecule and methods of their use for identifying, isolating, or detecting one or more antigen-specific T cells, and treating a disease, disorder, or condition, including cancer, are disclosed.

This invention provides a method, program, and apparatus for more easily designing delivery carriers suitable for target cells. [Solution] A method for predicting delivery carrier composition comprises the steps of preparing a delivery carrier prediction tool constructed by machine learning using a delivery carrier composition dataset of multiple types of delivery carriers exhibiting different component compositions, a non-target cell membrane composition dataset of multiple types of cells other than target cells relating to cell membrane lipid composition, and a non-target cell delivery amount dataset of multiple types of delivery carriers relating to the amount of delivery substances delivered to multiple types of cells other than target cells as training datasets, and using the delivery carrier prediction tool to obtain a delivery carrier composition that satisfies a target value based on the cell membrane lipid composition of target cells.

In some aspects, provided herein are methods for delivering a plurality of different gene editing complexes targeting genes or genetic motifs to cells, where the methods include subjecting a cell suspension comprising the cells to mechanical deformation, such as a material having pores therethrough, such as a filter. In other aspects, provided herein are systems, kits, and compositions useful in the methods taught herein.

A system comprised of customized nanoscopic projectiles directed to target cells. Projectiles are metered into a central force accelerator, comprised of hundreds to thousands of concurrent channels. Asperities of the channels' surface, transferring momentum from the central force accelerator to the projectiles, are atomic level asperities. Projectiles penetrate to target cells, deliver chemicals, without using the organism's circulatory system, resulting in cells being altered; killed if cancerous, modified by genetic materials contained in projectiles, and enhanced in performance by projectiles loaded with content to assist in cellular purposes.

The invention belongs to the technical field of biology, and particularly discloses a dsSAM50 / dsActin-coated MSNs nano-complex, a preparation method thereof and application of the dsSAM50 / dsActin-coated MSNs nano-complex in prevention and control of large thrips of cowpeas, dsSAM50 and dsActin are simultaneously loaded by adopting nano-carrier mesoporous silica nanoparticles (MSNs), double genes (dsSAM50 / dsActin) are loaded through the mesoporous silica nanoparticles (MSNs), and the dsSAM50 / dsActin-coated MSNs nano-complex is obtained through the preparation method of the dsSAM50 / dsActin-coated MSNs nano-complex and the preparation method of the dsSAM50 / dsActin-coated MSNs nano-complex. The technical bottlenecks that bare dsRNA is easy to degrade and low in delivery efficiency in the traditional RNAi technology are broken through. The complex significantly improves the cell delivery efficiency of lethal genes by virtue of the high load capacity and targeted release characteristic of the nano-material, not only can significantly inhibit the expression of SAM50 and Actin genes of the megalurothrips megalurothrips, but also can significantly reduce the fecundity of the megalurothrips megalurothrips, significantly improves the death rate of the megalurothrips megalurothrips, and has good application prospects. After the two dsRNAs and the MSNs form a complex, the control effect on the cowpea large thrips can be improved.

The invention provides a method for delivering mesenchymal stem cell mitochondria based on outer vesicle wrapping, and belongs to the field of stem cell delivery. The delivery system is composed of hybrid vesicles fixed with curcumin-sulfydryl derivatives and a mitochondrial preservation solution wrapped by the hybrid vesicles. The hybrid vesicle is composed of a mesenchymal stem cell membrane and a functionalized liposome; the dosage of the functionalized liposome is greater than or equal to that of the mesenchymal stem cell membrane. According to the mitochondrial delivery system provided by the invention, immune escape is realized through the mesenchymal stem cell membrane, and the in-vivo circulation time is prolonged; precise mitochondrial targeting is achieved through TPP modification. According to the invention, the curcumin-sulfydryl derivative is covalently anchored to the vesicle membrane, so that a dynamic anti-oxidation barrier is formed, whole-course protection is provided for mitochondria, membrane fusion is remarkably promoted, and the delivery efficiency is improved. Concentration-dependent toxicity and functional interference possibly caused by direct dissolution of curcumin in a preserving fluid are avoided, and synergism of protection and delivery is realized.

The invention discloses a novel porous microgel cell delivery system with high-throughput preparation capability, the system is composed of three parts, namely an aqueous two-phase system, a gas-assisted microfluidic device and a microporous microgel support, and can realize rapid and large-scale preparation of homogenized microgel, and the natural microporous structure in the microgel can be used for preparing a cell with high throughput. The survival and proliferation of various stem cells and somatic cells are facilitated, and high cell loading capacity and long-term activity maintenance are realized; the composite hydrogel between the microgels provides support for migration of endothelial cells and lumen formation, has good injectability and biocompatibility, and is matched with various tissue repair applications, and animal experiments find that in an ischemic stroke rat model, the composite hydrogel has a good application prospect. The microporous microgel loaded with the primary rat neural progenitor cells is injected, so that long-term neural function recovery of stroke rats can be effectively improved; the invention establishes a porous microgel delivery system with high throughput, high cell loading capacity and multiple vascularization functions, and the porous microgel delivery system is suitable for various tissue engineering applications.

Enhanced virus-like particles (eVLPs), comprising a membrane comprising a phospholipid bilayer with one or more virally-derived glycoproteins on the external side; and a cargo disposed in the core of the eVLP on the inside of the membrane, wherein the eVLP does not comprise an exogenous gag / pol protein, and methods of use thereof for delivery of the cargo to cells.

This invention provides a method for preparing and applying a class of Motixafortide-nitrogen mustard conjugates and their fluorescent probes, belonging to the fields of peptide preparation and biomedicine. This invention utilizes a solid-phase peptide synthesis method to covalently link the DNA alkylating agent nitrogen mustard with the CXCR4 targeting peptide Motixafortide, and further couple it with a fluorescent dye, successfully preparing a series of novel conjugates and their fluorescent probes. Experimental verification shows that the Motixafortide-nitrogen mustard conjugates and their fluorescent probes prepared in this invention can significantly enhance the antitumor activity and targeting of nitrogen mustard to tumor cells. Simultaneously, the rhodamine B-labeled dinitrogen mustard conjugate BCCR exhibits specific targeting of the CXCR4 receptor and dual targeting of the tumor cell nucleus. These conjugates enable real-time tracking of the entire process of tumor targeting, cell delivery, and nuclear localization, providing a powerful tool for efficacy evaluation and mechanism research, thus possessing promising clinical translational prospects and application value.

Provided herein are, inter alia, extracellular products (e.g., vesicles such as microvesicles, e.g., exosomes) produced by renal cells (such as bioactive renal cells, e.g., selected renal cells). Methods of altering components (such as miRNAs or proteins) of vesicles produced by cells, as well as methods of producing vesicles comprising various compounds are also included. Also provided are diagnostic and treatment methods.